These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37661878)

  • 1. Uncovering the System Vulnerability and Criticality of Human Brain Under Dynamical Neuropathological Events in Alzheimer's Disease.
    Zhang J; Liu Q; Zhang H; Dai M; Song Q; Yang D; Wu G; Chen M
    J Alzheimers Dis; 2023; 95(3):1201-1219. PubMed ID: 37661878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum.
    Jones DT; Graff-Radford J; Lowe VJ; Wiste HJ; Gunter JL; Senjem ML; Botha H; Kantarci K; Boeve BF; Knopman DS; Petersen RC; Jack CR
    Cortex; 2017 Dec; 97():143-159. PubMed ID: 29102243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
    Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.
    Quesnel MJ; Labonté A; Picard C; Zetterberg H; Blennow K; Brinkmalm A; Villeneuve S; Poirier J; ;
    Brain; 2024 May; 147(5):1680-1695. PubMed ID: 37992295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Grothe MJ; Sepulcre J; Gonzalez-Escamilla G; Jelistratova I; Schöll M; Hansson O; Teipel SJ;
    Brain; 2018 Sep; 141(9):2755-2771. PubMed ID: 30016411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
    Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
    Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease.
    Buchanan H; Mackay M; Palmer K; Tothová K; Katsur M; Platt B; Koss DJ
    Mol Neurobiol; 2020 Aug; 57(8):3258-3272. PubMed ID: 32514860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medial Temporal Lobe Networks in Alzheimer's Disease: Structural and Molecular Vulnerabilities.
    de Flores R; Das SR; Xie L; Wisse LEM; Lyu X; Shah P; Yushkevich PA; Wolk DA
    J Neurosci; 2022 Mar; 42(10):2131-2141. PubMed ID: 35086906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S; Kuceyeski A; Raj A;
    J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images.
    Malotaux V; Colmant L; Quenon L; Huyghe L; Gérard T; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
    J Alzheimers Dis; 2024; 97(1):421-433. PubMed ID: 38108350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
    Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
    Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline.
    Hammond TC; Xing X; Wang C; Ma D; Nho K; Crane PK; Elahi F; Ziegler DA; Liang G; Cheng Q; Yanckello LM; Jacobs N; Lin AL
    Commun Biol; 2020 Jul; 3(1):352. PubMed ID: 32632135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
    Takeda S
    Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study.
    Schoonhoven DN; Coomans EM; Millán AP; van Nifterick AM; Visser D; Ossenkoppele R; Tuncel H; van der Flier WM; Golla SSV; Scheltens P; Hillebrand A; van Berckel BNM; Stam CJ; Gouw AA
    Brain; 2023 Oct; 146(10):4040-4054. PubMed ID: 37279597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.